Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Carrefour becomes first European retailer to offer shopping on ChatGPT - 2False fuel prices in fabricated graphics circulate in Malaysia as Iran war continues
- 3Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
- 4The Manual for Decent European Urban communities in 2024
- 5'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- Benin coup thwarted by loyalist troops, president tells nation
- Doctor's orders: Eat ice cream, and other tips for a long and healthy life
- Instructions to Pick the Ideal Pre-assembled Home for Your Necessities
- General Atlantic says ‘biggest mistake’ would be pulling back on Gulf deals
- The most effective method to Pick the Right Material Organization: Your Definitive Aide
- Horror and fear in West Bank as Israel approves hanging Palestinians convicted of murdering Israelis
- We may be witnessing the messy death of a star in real time
- Building a Maintainable Closet: Individual Excursions in Moral Style
- Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
